<DOC>
	<DOCNO>NCT02217956</DOCNO>
	<brief_summary>HCIP show efficacy treatment peritoneal carcinosis colorectal background . Few study publish use HCIP peritoneal carcinosis ovarian background non-randomized phase II study small population use different type drug dosage . heterogeneity seem necessary standardize utilization modality HCIP peritoneal carcinosis ovarian background</brief_summary>
	<brief_title>Dose Escalation Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery Patients With Unresectable Stage IIIC Ovarian , Tube Peritoneal Primary Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Stage IIIC unresectable ovarian , tubes peritoneal primitive adenocarcinoma accord FIGO classification previously treat 6 cycle carboplatincisplatin neoadjuvant chemotherapy response allow complete surgery 6 cycle 2 . Time frame sixth platin injection CRS + HCIP &lt; 10 week 3 . No disease progression neoadjuvant chemotherapy 4 . 18 &lt; /= âge &lt; /= 65 an 5 . Performance Status OMS &lt; 2 6 . Hematological function : PNN &gt; /= 1.5x10^9/L , platelet &gt; /= 150x10^9/L , hemoglobin &gt; 9 g /dl ( transfusion allow ) 7 . Hepatic function : Bilirubin &lt; /= 1,5 x LSN , ASAT ( SGOT ) ALAT ( SGPT ) &lt; /= 3 x LSN , Phosphatases alkaline &lt; /= 3 x LSN 8 . No kidney relate pathology , plasmatic creatinine &lt; 140 µmol/l , creatinine clearance &gt; 60 ml/min ( Cockcroft formula ) urinary strip &lt; 2 ( If urinary strip &gt; /= 2 , proteinuria &lt; 1g/24h ) 9 . Plasmatic albumine &gt; 25 g/l 10 . HIV negative status 11 . Affiliation social security 12 . Signed informed consent 1 . Incomplete cell kill surgery 2 . Nonepithelial ovarian cancer 3 . Borderline tumor 4 . Non complete remission previous cancer 5 five year inclusion 5 . Uncontrolled high blood pressure ( blood pressure &gt; 150/100 mm Hg despite antihypertensive treatment ) 6 . Previous abdominal pelvic radiotherapy 7 . Previous pathology central nervous system , except well controlled pathology like epilepsy 8 . Previous stroke , transient ischemic attack subarachnoid hemorrhage 9 . Previous pulmonary embolism 10 . Pregnant breastfeed woman ( Women age must blood negative pregnancy test least 15 day go surgery ) 11 . Participation clinical trial within 30 day inclusion study 12 . Known hypersensitivity platin bevacizumab 13 . Not heal wound , ulcer bone fracture 14 . Previous haemorrhagic thrombotic malfunction &lt; 6 month 15 . Significant CArdiovascular disorder include : Heart attack unstable angina within 6 month inclusion Grade &gt; 1 congestive heart failure accord NYHA classification Uncontrolled cardiac arrhythmia despite treatment ( patient atrial fibrillation pace control include ) 16 . Long term recent ( within 10 day inclusion ) medication use Aspirin dosage &gt; 325 mg/day 17 . Long term recent ( within 10 day inclusion ) medication use anticoagulant per os parenteral thrombolytic give full dosage therapeutic purpose . 18 . Grade &gt; 1 previous sensory motor neuropathy accord CTC AE V4.0 19 . Previous abdominal fistula , GI perforation intraabdominal abscess within 6 month first administration bevacizumab 20 . Proof disease , metabolic malfunction , physical laboratory exam show possibility disease condition contraindicate administration drug trial exsposing patient several complication relate treatment . 21 . Persons deprive liberty 22 . Impossibility comply medical follow treatment geographical , social mental reason</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>